Drugs News and Research

RSS

FDA meeting streamlines pathway to initial U.S. approval of Provectus's PV-10 oncology drug

Provectus Biopharmaceuticals, Inc. (PVCT), a development-stage oncology and dermatology biopharmaceutical company, today announced that it has received the official minutes from the Type C meeting held with the FDA's Division of Oncology Products 2 on December 16, 2013.

27 Jan 2014

NextSource BioTechnology announces product re-launch, market availability of Lomustine in U.S.

NextSource BioTechnology, LLC, (NSB), an emerging Specialty Pharmaceutical Manufacturing and Marketing Company focused on Consolidating, Re-Branding and Launching "Matured & Orphan Drugs," has announced its most recent product Lomustine (CCNU), formerly known as CeeNu® by Bristol-Myers Squibb (BMS), which has officially been removed from the U.S. Food & Drug Administration (FDA) Drug Shortage List.

27 Jan 2014

Active Biotech, Teva remain committed to NERVENTRA clinical development program for multiple sclerosis

Teva Pharmaceutical Industries Ltd. and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that both companies remain committed to the NERVENTRA® (laquinimod) clinical development program for multiple sclerosis (MS) following the announcement of a negative opinion for the treatment of relapsing-remitting multiple sclerosis (RRMS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

27 Jan 2014

Study explores potential of antibody-drug conjugates and challenges in manufacturing them

After years of research, development and testing, a new class of drugs is emerging on the market with two frontrunners acting as harbingers of what's to come. The cover story in Chemical & Engineering News, ACS' weekly newsmagazine, explores the potential of these antibody-drug conjugates (ADCs) and the challenges in developing and manufacturing them.

27 Jan 2014

Omnicell’s Pandora business analytics solutions now available in the Middle East markets

Omnicell, Inc. (OMCL) today announced that its Pandora® business analytics solutions are now available for customers in the Middle East markets.

From Omnicell, Inc. 27 Jan 2014

NIBIO signs collaboration agreement for clinical development of new mucosal TB vaccines

Japan's National Institute of Biomedical Innovation ("NIBIO"), Aeras and Create Vaccine Company, Ltd ("CREATE") announce today that they signed a collaboration agreement on December 26, 2013, on the preclinical and clinical development of new mucosal tuberculosis (TB) vaccines based on NIBIO's human parainfluenza type-2 (rhPIV2) vector technology.

27 Jan 2014

Researchers develop novel compound known to reverse spread of malignant breast cancer cells

Researchers at Cardiff University are developing a novel compound known to reverse the spread of malignant breast cancer cells.

26 Jan 2014

Catalent files registration statement with SEC for initial public offering of common stock

Catalent Pharma Solutions announced today that Catalent, Inc. has publicly filed a registration statement with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its common stock.

25 Jan 2014

Viewpoints: Consumers awakening to health law's 'perverse incentives;' Medicaid expansion could help Dems in mid-term elections; new 'devious tactic' in smoking

With fewer glitches to deter them, millions of Americans are now logging on to the ObamaCare health-insurance-exchange websites. When they get there, many are discovering some unpleasant surprises:

25 Jan 2014

Antibe Therapeutics increases non-brokered private placement to a total of 2.27 million units

Antibe Therapeutics Inc. ("Antibe" or the "Corporation") (TSXV:ATE) announces an increase to the size of its non-brokered private placement to a total of approximately 2.27 million units (the "Units") at a price of $0.55 per Unit, from the previously announced total of approximately 1.8 million Units, each Unit comprised of one Common Share of the Corporation and one-half of one Common Share purchase warrant ("Warrant") with each whole Warrant entitling the holder to purchase an additional Common Share ("Warrant Share") at a price of $0.80 per Warrant Share for a term of thirty-six (36) months following the date of issuance, for gross proceeds of up to $1.25 million (the "Offering").

25 Jan 2014

Researchers identify important steps to understand mechanisms underlying pathogenic effect of prions

"When they are healthy, they look like tiny spheres; when they are malignant, they appear as cubes" stated Giuseppe Legname, principal investigator of the Prion Biology Laboratory at the Scuola Internazionale Superiore di Studi Avanzati (SISSA) in Trieste, when describing prion proteins.

25 Jan 2014

Increased inflammation following infection impairs brain's ability to form spatial memories

Increased inflammation following an infection impairs the brain's ability to form spatial memories - according to new research. The impairment results from a decrease in glucose metabolism in the brain's memory centre, disrupting the neural circuits involved in learning and memory.

25 Jan 2014

Study shows impulsive personalities more likely to report higher levels of food addiction

The same kinds of impulsive behavior that lead some people to abuse alcohol and other drugs may also be an important contributor to an unhealthy relationship with food, according to new research from the University of Georgia.

25 Jan 2014

New drugs for treatment of prostate cancer may not target root cause of the disease

NEW drugs being developed for the treatment of prostate cancer may not be targeting the root cause of the disease, according to research published today (Friday, 24 January 2014) in Cell Death & Differentiation.

25 Jan 2014

ADDF, Alzheimer's Society partner to provide funding for research in Alzheimer's disease

Today the Alzheimer's Drug Discovery Foundation and the Alzheimer's Society (UK) announced a new partnership that will provide funding for research in Alzheimer's disease and related dementias, with the goal of accelerating critical development programs and bringing new treatments to patients. The partnership intends to fund projects up to $1.5 million each focused on drug repurposing, leveraging existing scientific evidence and research to accelerate the drug development process.

24 Jan 2014

Researchers suggest possible novel target for seizure-blocking medicines

Researchers in the biomedical engineering department at Case Western Reserve University have found that epileptic activity can spread through a part of the brain in a new way, suggesting a possible novel target for seizure-blocking medicines.

24 Jan 2014

Bristol-Myers Squibb fourth quarter 2013 revenues increase 6% to $4.4 billion

Bristol-Myers Squibb Company today reported results for the fourth quarter and full year of 2013. The fourth quarter was highlighted by the company's announcement to sell its diabetes business as part of the continued evolution of its successful BioPharma strategy to a specialty care model. The company achieved important regulatory milestones in the quarter for Eliquis in the U.S., daclatasvir/asunaprevir in Japan, daclatasvir in Europe and Farxiga in the U.S. In addition, the company provided financial guidance for 2014.

24 Jan 2014

Researchers locate two molecules involved in perpetuating chronic pain

Setting the stage for possible advances in pain treatment, researchers at The Johns Hopkins University and the University of Maryland report they have pinpointed two molecules involved in perpetuating chronic pain in mice. The molecules, they say, also appear to have a role in the phenomenon that causes uninjured areas of the body to be more sensitive to pain when an area nearby has been hurt.

24 Jan 2014

Researchers reveal how genetic susceptibility plays large role in cancer risk

In laboratory experiments conducted on human cell lines at the Johns Hopkins Kimmel Cancer Center, scientists have shown that people carrying certain mutations in two hereditary cancer genes, BRCA2 and PALB2, may have a higher than usual susceptibility to DNA damage caused by a byproduct of alcohol, called acetaldehyde.

24 Jan 2014

Scientists figure out key step in how free calcium is controlled in the body

Scientists at Johns Hopkins report they have figured out a key step in how "free" calcium - the kind not contained in bones - is managed in the body, a finding that could aid in the development of new treatments for a variety of neurological disorders that include Parkinson's disease.

24 Jan 2014

Drugs News and Research

FDA meeting streamlines pathway to initial U.S. approval of Provectus's PV-10 oncology drug

NextSource BioTechnology announces product re-launch, market availability of Lomustine in U.S.

Active Biotech, Teva remain committed to NERVENTRA clinical development program for multiple sclerosis

Study explores potential of antibody-drug conjugates and challenges in manufacturing them

Omnicell’s Pandora business analytics solutions now available in the Middle East markets

NIBIO signs collaboration agreement for clinical development of new mucosal TB vaccines

Researchers develop novel compound known to reverse spread of malignant breast cancer cells

Catalent files registration statement with SEC for initial public offering of common stock

Viewpoints: Consumers awakening to health law's 'perverse incentives;' Medicaid expansion could help Dems in mid-term elections; new 'devious tactic' in smoking

Antibe Therapeutics increases non-brokered private placement to a total of 2.27 million units

Researchers identify important steps to understand mechanisms underlying pathogenic effect of prions

Increased inflammation following infection impairs brain's ability to form spatial memories

Study shows impulsive personalities more likely to report higher levels of food addiction

New drugs for treatment of prostate cancer may not target root cause of the disease

ADDF, Alzheimer's Society partner to provide funding for research in Alzheimer's disease

Researchers suggest possible novel target for seizure-blocking medicines

Bristol-Myers Squibb fourth quarter 2013 revenues increase 6% to $4.4 billion

Researchers locate two molecules involved in perpetuating chronic pain

Researchers reveal how genetic susceptibility plays large role in cancer risk

Scientists figure out key step in how free calcium is controlled in the body

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News